Supreme Court Issues Notice In Plea Seeking Guidelines Against Manufacturing And Selling Of Fake Pharma Drugs

The Supreme Court issued a notice to the central government on a petition seeking stricter guidelines to combat the manufacturing and sale of counterfeit pharmaceutical drugs. The plea emphasized the alarming prevalence of fake medicines in the country, posing severe risks to public health and safety. The petitioner argued that the existing laws are inadequate to address the scale of the issue and called for more robust measures, including stricter enforcement mechanisms. Acknowledging the significance of the matter, the bench agreed to examine whether the current legal framework needs strengthening to effectively curb this menace. The case highlights the judiciary’s role in addressing public health challenges and ensuring the safety of citizens against fraudulent practices in the pharmaceutical sector.